Moderna's Cancer Vaccine Shows Promise, Stock Valuation Raises Concerns
Moderna's stock has surged over 600% this year, reaching a market cap close to 90000 million dollars, driven by positive clinical trial results for its cancer vaccine, intismeran, developed in collaboration with Merck. On Aug. 19, phase 3 trial results indicated that intismeran, when combined with Merck's Keytruda, significantly reduced the risk of death and cancer recurrence in melanoma patients. Despite the promising results, the vaccine has not yet received approval, and there are concerns about the stock's inflated valuation. Investors may be overestimating the potential for intismeran to treat multiple cancers, which remains uncertain. Additionally, the production of a personalized cancer vaccine at scale poses operational challenges and costs. The profit-sharing agreement between Moderna and Merck could further limit Moderna's long-term profitability. Given these factors, the current stock price may not be sustainable, and potential investors should exercise caution.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027

Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Care

Real-Life Theranos: New Blood Testing Startup Claims to Predict Health Risks

Novartis Raises Sales Forecast for Three Major Drugs to $18 Billion, Expected Annual Growth Rate of 5% by 2031

Sellas Life Sciences Cancer Vaccine Extends Patient Survival in Blood Cancer Clinical Trial

NVIDIA Launches Nemotron for Science to Accelerate Scientific Discoveries with Intelligent Agents

FDA Rejects Approval of Kangfang Biotech's Cancer Drug Ivonescimab

Former Employee Sues Ethereum Foundation, Claims Retaliatory Dismissal After Protesting 'Seppuku' Clause

BRT.Fit Founder Calls for Incorporating Exercise Habits into Cancer Prevention

Nixo sues Ethereum Foundation, Vitalik Buterin over 'suicide pledge' claim

U.S. Senate Rejects Long-Term Regulation Legislation for the Cryptocurrency Industry

Proteomic clocks link accelerated aging to higher risk of death and disease

Aging is not linear: cells go through coordinated stages of deterioration

Trump and Islamophobia: The Chorus That No Longer Mobilizes Votes

Jennifer Tilly Earns Up to $10 Million a Year from The Simpsons Without Ever Participating: Her Story

UK to ban crypto exchanges from making markets on their own platforms as Bitcoin rules change

Here Are the 4 Investing Rules I'm Never Breaking, No Matter How Scary the Stock Market Gets

Mr&强 Discusses Highlights of the ORIPA Project

Gold and silver lose $15 trillion, Bitcoin holds up better

Why Bitcoin’s quantum security upgrade may take years

The Industry Is Not Bad, But the $350 Billion Lost by ETH and SOL Is the Root Cause of Industry Pessimism

Prediction: These Will Be AMD’s and Nvidia’s Stock Prices by 2028

Crypto: Netflix Series on FTX Sparks Reactions from CZ and Vitalik Buterin

Solana upgrades to mainnet 1.0 as Foundation takes majority CoinGecko stake

IOSCO Warns of 'Quantum Delay' and Assesses Readiness for Quantum Threat

Deribit outage hit Bitcoin hedgers on Coinbase

Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy?

J.P. Morgan Says Tesla's Robotaxi Fleet Could Match Waymo's Miles by Late 2027 With 18,000 Cars. The Number That Matters Is How Much Each Car Earns.

What's Going on with The Trade Desk Stock? 3 Reasons Investors Are Losing Confidence.









